SEC Form 4 · accession 0001144204-15-018866

Protea Biosciences Group, Inc. · PRGB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Mar 20, 2015

Accepted (ET)

Mar 27, 2015 · 1:21 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001335103

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Mar 20, 2015	J	2,201,046	—	A	14,885,481	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Warrant (right to buy)^F1,F2	$0.50	Mar 20, 2015	J	1,100,523	A	Mar 20, 2015	Mar 20, 2020	Common Stock	1,100,523	1,100,523	I

F1On March 20, 2015, the Issuer's Board of Directors authorized the conversion of an aggregate of $$341,084.81 principal amount of, and $192,784.63 of accrued interest on promissory notes issued by the Issuer to Summit Resources, Inc. ("Summit"), and $16,392.14 of accounts payable by the Issuer to Summit, into 2,201,046 units of securities, each unit consisting of one share of the Issuer's common stock and a five-year warrant to purchase one-half share of Common Stock, at an exercise price of $0.50 per whole share, at a conversion price of $0.25 per unit. None of these obligations was convertible by its terms.
F2Represents the shares of Common Stock owned of record by Summit. Steve Antoline has voting and dispositive control over any securities owned of record by Summit and may be deemed to beneficially own the shares of common stock held of record by Summit.